Abstract
Purpose
Breast cancer is a significant global public health issue. It is the leading cause of death among women around the world, with an incidence increasing annually. In recent years, there has been more and more information in the literature regarding a protective role of vitamin D in cancer. Increasingly preclinical and clinical studies suggest that vitamin D optimal levels can reduce the risk of breast cancer development and regulate cancer-related pathways.
Method
In this review, we focus on the importance of vitamin D in breast cancers, discussing especially the influence of vitamin D signaling on estrogen receptor and human epidermal growth factor receptor 2 (HER2), two major biomarkers of breast cancer today.
Conclusion
We discuss the possibility of actual and future targeted therapeutic approaches for vitamin D signaling in breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- AIs:
-
Aromatase inhibitors
- ARs:
-
Retinoic acid receptors
- BC:
-
Breast cancer
- cAMP:
-
Cyclic adenosine monophosphate
- CRE:
-
cAMP-responsive element
- CDH1:
-
Cadherin 1
- CDK:
-
Cyclin-dependent kinase
- COX2:
-
Cyclooxygenase 2
- CTSL:
-
Cathepsin L
- CYP:
-
Cytochrome P450
- CYP27A1:
-
25α-Hydroxylase
- CYP27B1:
-
1α-Hydroxylase
- DBD:
-
DNA-binding domain
- DFS:
-
Disease-free survival
- EDF:
-
Endoxifen
- ER:
-
Estrogen receptor
- FXRs:
-
Farnesoid X receptors
- HER2:
-
Human epidermal growth factor receptor 2
- HIF1α:
-
Hypoxia-inducible factor 1α
- HDT:
-
4-Hydroxytamoxifen
- IGF:
-
Insulin-like growth factor
- IGF1:
-
Insulin-like growth factor 1
- IL-6:
-
Interleukin-6
- LBD:
-
Ligand-binding domain
- LXRs:
-
Liver X receptors
- MAPKP5:
-
Mitogen-activated protein kinase phosphatase 5
- MMP1:
-
Matrix metalloproteinase 1
- MMP9:
-
Matrix metalloproteinase 9
- NDT:
-
N-desmethyl tamoxifen
- NF-κB:
-
Nuclear factor-κB
- NRs:
-
Nuclear hormone receptors
- OS:
-
Overall survival
- PPARs:
-
Peroxisome proliferator-activated receptors
- PARPi:
-
Inhibitors of poly(ADP-ribose) polymerase
- PG:
-
Prostaglandin
- 15-PGDH:
-
15-Hydroxyprostaglandin dehydrogenase
- PGE2:
-
Prostaglandin E2
- PR:
-
Progesterone receptor
- RTKs:
-
Receptor tyrosine kinases
- RXRs:
-
Retinoid X receptors
- SAM:
-
Selective aromatase modulators
- STAT3:
-
Signal transducer and activator of transcription 3
- TGF-β:
-
Transforming growth factor-β
- TNF-α:
-
Tumor necrosis factor-α
- SERMs:
-
Selective ER modulators
- SERDs:
-
Selective ER down-regulators
- SNPs:
-
Germline single nucleotide polymorphisms
- TAM:
-
Tamoxifen
- TIMP1:
-
Tissue inhibitor of metalloproteinases 1
- TNBC:
-
Triple-negative breast cancers
- TRs:
-
Thyroid hormone receptors
- VDR:
-
Vitamin D receptor
- VDREs:
-
Vitamin D response elements
- VEGF:
-
Vascular endothelial growth factor
References
Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J (2008) Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer–results of a large case-control study. Carcinogenesis 29:93–99. doi:10.1093/carcin/bgm240
Anderson WF, Chatterjee N, Ershler WB, Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 76:27–36
Antunes MV et al (2015) Influence of CYP2D6 and CYP3A4 phenotypes, drug interactions, and vitamin D status on tamoxifen biotransformation. Ther Drug Monit 37:733–744. doi:10.1097/FTD.0000000000000212
Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463–475. doi:10.1038/nrc2656
Beatson G (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 148:104–107. doi:10.1016/s0140-6736(01)72307-0
Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE (2005) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomark Prev 14:1991–1997. doi:10.1158/1055-9965.EPI-04-0722
Bettoun DJ et al (2003) Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation. Mol Endocrinol 17:2320–2328. doi:10.1210/me.2003-0148
Blackmore KM, Lesosky M, Barnett H, Raboud JM, Vieth R, Knight JA (2008) Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer. Am J Epidemiol 168:915–924. doi:10.1093/aje/kwn198
Brauch H, Murdter TE, Eichelbaum M, Schwab M (2009) Pharmacogenomics of tamoxifen therapy. Clin Chem 55:1770–1782. doi:10.1373/clinchem.2008.121756
Brodie AM et al (2001) Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 79:41–47
Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM (1999) Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140:27–35
Bulun SE, Simpson ER (2008) Aromatase expression in women’s cancers. Adv Exp Med Biol 630:112–132
Bulun SE, Lin Z, Zhao H, Lu M, Amin S, Reierstad S, Chen D (2009) Regulation of aromatase expression in breast cancer tissue. Ann N Y Acad Sci 1155:121–131. doi:10.1111/j.1749-6632.2009.03705.x
Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, Nauta RJ, Evans SR (1994) Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat 31:191–202
Cadoo KA, Fornier MN, Morris PG (2013) Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Quart J Nucl Med Mol Imag 57:312–321
Carson MW et al (2014) HDX reveals unique fragment ligands for the vitamin D receptor. Bioorg Med Chem Lett 24:3459–3463. doi:10.1016/j.bmcl.2014.05.070
Chan HJ, Petrossian K, Chen S (2015) Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells. J Steroid Biochem Mol Biol. doi:10.1016/j.jsbmb.2015.07.018
Chen S (1998) Aromatase and breast cancer. Front Biosci 3:d922–d933
Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H (2010) Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat 121:469–477. doi:10.1007/s10549-009-0593-9
Chen P et al (2013) Higher blood 25(OH)D level may reduce the breast cancer risk: evidence from a Chinese population based case-control study and meta-analysis of the observational studies. PLoS ONE 8:e49312. doi:10.1371/journal.pone.0049312
Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW (2004) Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci USA 101:7711–7715. doi:10.1073/pnas.0402490101
Chiang KC et al (2016) The vitamin D analog, MART-10, attenuates triple negative breast cancer cells metastatic potential. Int J Mol Sci. doi:10.3390/ijms17040606
Chlebowski RT et al (2008) Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 100:1581–1591. doi:10.1093/jnci/djn360
Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G (2016) Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 96:365–408. doi:10.1152/physrev.00014.2015
Christensen GL, Jepsen JS, Fog CK, Christensen IJ, Lykkesfeldt AE (2004) Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment. Breast Cancer Res Treat 85:53–63. doi:10.1023/B:BREA.0000021047.37869.95
Colston KW (2008) Vitamin D and breast cancer risk. Best Pract Res Clin Endocrinol Metab 22:587–599. doi:10.1016/j.beem.2008.08.002
Crew KD (2013) Vitamin d: are we ready to supplement for breast cancer prevention and treatment? ISRN Oncol 2013:483687. doi:10.1155/2013/483687
Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, Hershman DL (2009) High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 27:2151–2156. doi:10.1200/JCO.2008.19.6162
Cross HS (2007) Extrarenal vitamin D hydroxylase expression and activity in normal and malignant cells: modification of expression by epigenetic mechanisms and dietary substances. Nutr Rev 65:S108–S112
Davies GL (2003) Cyclooxygenase-2 and chemoprevention of breast cancer. J Steroid Biochem Mol Biol 86:495–499
Davies G, Martin LA, Sacks N, Dowsett M (2002) Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol ESMO 13:669–678
deConinck EC, McPherson LA, Weigel RJ (1995) Transcriptional regulation of estrogen receptor in breast carcinomas. Mol Cell Biol 15:2191–2196
DeLuca HF (2008) Evolution of our understanding of vitamin D. Nutr Rev 66:S73–S87. doi:10.1111/j.1753-4887.2008.00105.x
den Hollander P, Savage MI, Brown PH (2013) Targeted therapy for breast cancer prevention. Front Oncol 3:250. doi:10.3389/fonc.2013.00250
Diaz L, Diaz-Munoz M, Garcia-Gaytan AC, Mendez I (2015) Mechanistic effects of calcitriol in cancer biology. Nutrients 7:5020–5050. doi:10.3390/nu7065020
Ditsch N et al (2012) The association between vitamin D receptor expression and prolonged overall survival in breast cancer. J Histochem Cytochem 60:121–129. doi:10.1369/0022155411429155
Ditsch N et al (2013) Thyroid hormone receptor (TR)alpha and TRbeta expression in breast cancer. Histol Histopathol 28:227–237
Elster N, Collins DM, Toomey S, Crown J, Eustace AJ, Hennessy BT (2015) HER2-family signalling mechanisms, clinical implications and targeting in breast cancer. Breast Cancer Res Treat 149:5–15. doi:10.1007/s10549-014-3250-x
Enjuanes A et al (2003) Regulation of CYP19 gene expression in primary human osteoblasts: effects of vitamin D and other treatments. Eur J Endocrinol 148:519–526
Escaleira MT, Sonohara S, Brentani MM (1993) Sex steroids induced up-regulation of 1,25-(OH)2 vitamin D3 receptors in T 47D breast cancer cells. J Steroid Biochem Mol Biol 45:257–263
Farmer H et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921. doi:10.1038/nature03445
Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ (2014) The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 14:342–357. doi:10.1038/nrc3691
Flanagan L, Packman K, Juba B, O’Neill S, Tenniswood M, Welsh J (2003) Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J Steroid Biochem Mol Biol 84:181–192
Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS (2004) Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64:1522–1533
Friebel TM, Domchek SM, Rebbeck TR (2014) Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst 106:dju091. doi:10.1093/jnci/dju091
Gandini S et al (2011) Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 128:1414–1424. doi:10.1002/ijc.25439
Garland CF, Gorham ED, Mohr SB, Garland FC (2009) Vitamin D for cancer prevention: global perspective. Ann Epidemiol 19:468–483. doi:10.1016/j.annepidem.2009.03.021
Gonzalez-Suarez I et al (2011) A new pathway that regulates 53BP1 stability implicates cathepsin L and vitamin D in DNA repair. EMBO J 30:3383–3396. doi:10.1038/emboj.2011.225
Gonzalo S (2014) Novel roles of 1 alpha, 25(OH)2D3 on DNA repair provide new strategies for breast cancer treatment. J Steroid Biochem Mol Biol 144(Pt A):59–64. doi:10.1016/j.jsbmb.2013.09.009
Grotsky DA et al (2013) BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells. J Cell Biol 200:187–202. doi:10.1083/jcb.201204053
Harris RE, Casto BC, Harris ZM (2014) Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol 5:677–692. doi:10.5306/wjco.v5.i4.677
Hart CD, Migliaccio I, Malorni L, Guarducci C, Biganzoli L, Di Leo A (2015) Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol 12:541–552. doi:10.1038/nrclinonc.2015.99
Heaney RP, Horst RL, Cullen DM, Armas LA (2009) Vitamin D3 distribution and status in the body. J Am Coll Nutr 28:252–256
Helleday T, Bryant HE, Schultz N (2005) Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 4:1176–1178
Higgins MJ, Stearns V (2011) Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 62:281–293. doi:10.1146/annurev-med-070909-182545
Hirshfield KM, Ganesan S (2014) Triple-negative breast cancer: molecular subtypes and targeted therapy. Curr Opin Obstet Gynecol 26:34–40. doi:10.1097/GCO.0000000000000038
Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354. doi:10.1038/nrc1609
James SY, Mackay AG, Binderup L, Colston KW (1994) Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J Endocrinol 141:555–563
Jaspers JE et al (2013) Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 3:68–81. doi:10.1158/2159-8290.CD-12-0049
Jatoi I, Benson JR (2016) Management of women with a hereditary predisposition for breast cancer. Future Oncol 12:2277–2288. doi:10.2217/fon-2016-0186
Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R (2015) ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer Nature reviews. Clin Oncol 12:573–583. doi:10.1038/nrclinonc.2015.117
Johnston SR, Dowsett M (2003) Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 3:821–831. doi:10.1038/nrc1211
Jones G (2007) Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin Dial 20:316–324. doi:10.1111/j.1525-139X.2007.00302.x
Kailajarvi ME, Salminen EK, Paija OM, Virtanent AM, Leino AE, Irjala KA (2004) Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy. Anticancer Res 24:1271–1274
Kalimutho M, Parsons K, Mittal D, Lopez JA, Srihari S, Khanna KK (2015) Targeted therapies for triple-negative breast cancer: combating a stubborn disease. Trends Pharmacol Sci. doi:10.1016/j.tips.2015.08.009
Karunagaran D et al (1996) ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15:254–264
Kawase T et al (2010) Association between vitamin D and calcium intake and breast cancer risk according to menopausal status and receptor status in Japan. Cancer Sci 101:1234–1240. doi:10.1111/j.1349-7006.2010.01496.x
Khan QJ, O’Dea AP, Sharma P (2010) Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. J Oncol. doi:10.1155/2010/654348
Khan MI, Bielecka ZF, Najm MZ, Bartnik E, Czarnecki JS, Czarnecka AM, Szczylik C (2014) Vitamin D receptor gene polymorphisms in breast and renal cancer: current state and future approaches (review). Int J Oncol 44:349–363. doi:10.3892/ijo.2013.2204
Kim Y, Je Y (2014) Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br J Cancer 110:2772–2784. doi:10.1038/bjc.2014.175
Kim HJ et al (2011) Vitamin D deficiency is correlated with poor outcomes in patients with luminal-type breast cancer. Ann Surg Oncol 18:1830–1836. doi:10.1245/s10434-010-1465-6
Kim HJ, Koh BS, Yu JH, Lee JW, Son BH, Kim SB, Ahn SH (2014) Changes in serum hydroxyvitamin D levels of breast cancer patients during tamoxifen treatment or chemotherapy in premenopausal breast cancer patients. Eur J Cancer 50:1403–1411. doi:10.1016/j.ejca.2014.02.026
Kinuta K, Tanaka H, Moriwake T, Aya K, Kato S, Seino Y (2000) Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology 141:1317–1324. doi:10.1210/endo.141.4.7403
Krishnan AV, Feldman D (2011) Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 51:311–336. doi:10.1146/annurev-pharmtox-010510-100611
Krishnan AV, Swami S, Feldman D (2010a) Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling. J Steroid Biochem Mol Biol 121:343–348. doi:10.1016/j.jsbmb.2010.02.009
Krishnan AV, Swami S, Peng L, Wang J, Moreno J, Feldman D (2010b) Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 151:32–42. doi:10.1210/en.2009-0855
Krishnan AV, Swami S, Feldman D (2012) The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer. Steroids 77:1107–1112. doi:10.1016/j.steroids.2012.06.005
LaPorta E, Welsh J (2014) Modeling vitamin D actions in triple negative/basal-like breast cancer. J Steroid Biochem Mol Biol 144(Pt A):65–73. doi:10.1016/j.jsbmb.2013.10.022
Lee HJ et al (2008) Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer Prev Res (Phila) 1:476–484. doi:10.1158/1940-6207.CAPR-08-0084
Lee HJ et al (2010) Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. J Steroid Biochem Mol Biol 121:408–412. doi:10.1016/j.jsbmb.2010.03.053
Leyssens C, Verlinden L, Verstuyf A (2014) The future of vitamin D analogs. Front Physiol 5:122. doi:10.3389/fphys.2014.00122
Litzenburger BC, Brown PH (2014) Advances in preventive therapy for estrogen-receptor-negative breast cancer. Curr Breast Cancer Rep 6:96–109. doi:10.1007/s12609-014-0144-1
Liu NQ, Hewison M (2012) Vitamin D, the placenta and pregnancy. Arch Biochem Biophys 523:37–47. doi:10.1016/j.abb.2011.11.018
Livraghi L, Garber JE (2015) PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med 13:188. doi:10.1186/s12916-015-0425-1
Lopes N et al (2012) 1Alpha,25-dihydroxyvitamin D3 induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation. Anticancer Res 32:249–257
Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, Colston KW (2005) Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 41:1164–1169. doi:10.1016/j.ejca.2005.01.017
Lumachi F, Santeufemia DA, Basso SM (2015) Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem 6:231–239. doi:10.4331/wjbc.v6.i3.231
Lundqvist J, Hansen SK, Lykkesfeldt AE (2013) Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase. Biochim Biophys Acta 1833:40–47. doi:10.1016/j.bbamcr.2012.10.012
Lundqvist J, Yde CW, Lykkesfeldt AE (2014) 1alpha, 25-dihydroxyvitamin D3 inhibits cell growth and NFkappaB signaling in tamoxifen-resistant breast cancer cells. Steroids 85:30–35. doi:10.1016/j.steroids.2014.04.001
McCullough ML, Rodriguez C, Diver WR, Feigelson HS, Stevens VL, Thun MJ, Calle EE (2005) Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomark Prev 14:2898–2904. doi:10.1158/1055-9965.EPI-05-0611
Milani A, Geuna E, Mittica G, Valabrega G (2014) Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. World J Clin Oncol 5:990–1001. doi:10.5306/wjco.v5.i5.990
Montemurro F, Di Cosimo S, Arpino G (2013) Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Annals Oncol/ESMO 24:2715–2724. doi:10.1093/annonc/mdt287
Mun MJ, Kim TH, Hwang JY, Jang WC (2015) Vitamin D receptor gene polymorphisms and the risk for female reproductive cancers: a meta-analysis. Maturitas 81:256–265. doi:10.1016/j.maturitas.2015.03.010
Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9:631–643. doi:10.1038/nrc2713
Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 123:21–27
Narvaez CJ, Matthews D, LaPorta E, Simmons KM, Beaudin S, Welsh J (2014) The impact of vitamin D in breast cancer: genomics, pathways, metabolism. Front Physiol 5:213. doi:10.3389/fphys.2014.00213
Nemenqani DM, Karam RA, Amer MG (2015) Abd El Rahman TM. Vitamin D receptor gene polymorphisms and steroid receptor status among Saudi women with breast cancer Gene 558:215–219. doi:10.1016/j.gene.2014.12.065
Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU (2013) Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast 22:525–531. doi:10.1016/j.breast.2012.12.006
Orlov I, Rochel N, Moras D, Klaholz BP (2012) Structure of the full human RXR/VDR nuclear receptor heterodimer complex with its DR3 target DNA. EMBO J 31:291–300. doi:10.1038/emboj.2011.445
Pickholtz I et al (2014) Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and growth inhibition of breast cancer cells and cancer stem-like cells. Oncotarget 5:11827–11846. doi:10.18632/oncotarget.2582
Radermacher J, Diesel B, Seifert M, Tilgen W, Reichrath J, Fischer U, Meese E (2006) Expression analysis of CYP27B1 in tumor biopsies and cell cultures. Anticancer Res 26:2683–2686
Rainville C, Khan Y, Tisman G (2009) Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series. Cases J 2:8390. doi:10.4076/1757-1626-2-8390
Reimers LL et al (2015) Vitamin D-related gene polymorphisms, plasma 25-hydroxyvitamin D, and breast cancer risk. CCC 26:187–203. doi:10.1007/s10552-014-0497-9
Richards SE, Weierstahl KA, Kelts JL (2015) Vitamin D effect on growth and vitamin D metabolizing enzymes in triple-negative breast cancer. Anticancer Res 35:805–810
Riemsma R, Forbes CA, Kessels A, Lykopoulos K, Amonkar MM, Rea DW, Kleijnen J (2010) Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat 123:9–24. doi:10.1007/s10549-010-0974-0
Ristimaki A et al (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62:632–635
Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D (2000) The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 5:173–179
Rollison DE et al (2012) Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U.S. Breast Cancer Res Treat 132:683–691. doi:10.1007/s10549-011-1885-4
Romagnolo AP, Romagnolo DF, Selmin OI (2015) BRCA1 as target for breast cancer prevention and therapy. Anti Cancer Agents Med Chem 15:4–14
Rose AA, Elser C, Ennis M, Goodwin PJ (2013) Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis. Breast Cancer Res Treat 141:331–339. doi:10.1007/s10549-013-2713-9
Roskoski R Jr (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79:34–74. doi:10.1016/j.phrs.2013.11.002
Ross JS et al (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307–325
Ross AC et al (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metabol 96:53–58. doi:10.1210/jc.2010-2704
Rubin GL, Zhao Y, Kalus AM, Simpson ER (2000) Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 60:1604–1608
Santini D et al (2010) Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients. Ann Oncol 21:185–186. doi:10.1093/annonc/mdp497
Santos-Martinez N et al (2014) Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach. BMC Cancer 14:230. doi:10.1186/1471-2407-14-230
Simboli-Campbell M, Narvaez CJ, van Weelden K, Tenniswood M, Welsh J (1997) Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 42:31–41
Simpson ER et al (2002) Aromatase–a brief overview. Annu Rev Physiol 64:93–127. doi:10.1146/annurev.physiol.64.081601.142703
So JY et al (2013) Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression. Cancer Prev Res 6:959–970. doi:10.1158/1940-6207.CAPR-13-0087
Stambolsky P et al (2010) Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 17:273–285. doi:10.1016/j.ccr.2009.11.025
Stocklin E, Eggersdorfer M (2013) Vitamin D, an essential nutrient with versatile functions in nearly all organs. Int J Vitam Nutr Res 83:92–100. doi:10.1024/0300-9831/a000151
Stoica A, Saceda M, Fakhro A, Solomon HB, Fenster BD, Martin MB (1999) Regulation of estrogen receptor-alpha gene expression by 1, 25-dihydroxyvitamin D in MCF-7 cells. J Cell Biochem 75:640–651
Swami S, Krishnan AV, Feldman D (2000) 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 6:3371–3379
Swami S, Krishnan AV, Peng L, Lundqvist J, Feldman D (2013) Transrepression of the estrogen receptor promoter by calcitriol in human breast cancer cells via two negative vitamin D response elements. Endocr Relat Cancer 20:565–577. doi:10.1530/ERC-12-0281
Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S (1997) 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science 277:1827–1830
Tanaka S, Haji M, Takayanagi R, Tanaka S, Sugioka Y, Nawata H (1996) 1,25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts. Endocrinology 137:1860–1869. doi:10.1210/endo.137.5.8612525
Teft WA et al (2013) CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res Treat 139:95–105. doi:10.1007/s10549-013-2511-4
Thakkar A, Wang B, Picon-Ruiz M, Buchwald P, Ince TA (2016) Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer. Breast Cancer Res Treat 157:77–90. doi:10.1007/s10549-016-3807-y
Thill M et al (2015) Combined treatment of breast cancer cell lines with vitamin D and COX-2 inhibitors. Anticancer Res 35:1189–1195
Tian XQ, Chen TC, Matsuoka LY, Wortsman J, Holick MF (1993) Kinetic and thermodynamic studies of the conversion of previtamin D3 to vitamin D3 in human skin. J Biol Chem 268:14888–14892
Voudouri K, Berdiaki A, Tzardi M, Tzanakakis GN, Nikitovic D (2015) Insulin-like growth factor and epidermal growth factor signaling in breast cancer cell growth: focus on endocrine resistant disease. Anal Cell Pathol 2015:975495. doi:10.1155/2015/975495
Welsh J (2007a) Targets of vitamin D receptor signaling in the mammary gland. J Bone Miner Res 22(Suppl 2):V86–V90. doi:10.1359/jbmr.07s204
Welsh J (2007b) Vitamin D and prevention of breast cancer. Acta Pharmacol Sin 28:1373–1382. doi:10.1111/j.1745-7254.2007.00700.x
Welsh J (2011) Vitamin D metabolism in mammary gland and breast cancer. Mol Cell Endocrinol 347:55–60. doi:10.1016/j.mce.2011.05.020
Welsh J, Wietzke JA, Zinser GM, Byrne B, Smith K, Narvaez CJ (2003) Vitamin D-3 receptor as a target for breast cancer prevention. J Nutr 133:2425S–2433S
Wolff AC et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Am Soc Clin Oncol 31:3997–4013. doi:10.1200/JCO.2013.50.9984
Woode DR, Aiyer HS, Sie N, Zwart AL, Li L, Seeram NP, Clarke R (2012) Effect of berry extracts and bioactive compounds on fulvestrant (ICI 182,780) sensitive and resistant cell lines. Int J Breast Cancer 2012:147828. doi:10.1155/2012/147828
Yanase T, Suzuki S, Goto K, Nomura M, Okabe T, Takayanagi R, Nawata H (2003) Aromatase in bone: roles of Vitamin D3 and androgens. J Steroid Biochem Mol Biol 86:393–397
Yao S et al (2011) Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. PLoS ONE 6:e17251. doi:10.1371/journal.pone.0017251
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137. doi:10.1038/35052073
Yde CW, Emdal KB, Guerra B, Lykkesfeldt AE (2012) NFkappaB signaling is important for growth of antiestrogen resistant breast cancer cells. Breast Cancer Res Treat 135:67–78. doi:10.1007/s10549-012-2053-1
Yen PM (2015) Classical nuclear hormone receptor activity as a mediator of complex biological responses: a look at health and disease. Best Pract Res Clin Endocrinol Metab 29:517–528. doi:10.1016/j.beem.2015.07.005
Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H (2010) Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer 46:2196–2205. doi:10.1016/j.ejca.2010.03.037
Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M (2001) Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metabol 86:888–894. doi:10.1210/jcem.86.2.7220
Zeichner SB et al (2015) Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer. Clin Breast Cancer 15:e1–11. doi:10.1016/j.clbc.2014.08.001
Zella LA, Kim S, Shevde NK, Pike JW (2007) Enhancers located in the vitamin D receptor gene mediate transcriptional autoregulation by 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 103:435–439. doi:10.1016/j.jsbmb.2006.12.019
Zembutsu H (2015) Pharmacogenomics toward personalized tamoxifen therapy for breast cancer. Pharmacogenomics 16:287–296. doi:10.2217/pgs.14.171
Zhang K, Song L (2014) Association between vitamin D receptor gene polymorphisms and breast cancer risk: a meta-analysis of 39 studies. PLoS ONE 9:e96125. doi:10.1371/journal.pone.0096125
Zhou D, Chen S (1999) Identification and characterization of a cAMP-responsive element in the region upstream from promoter 1.3 of the human aromatase gene. Arch Biochem Biophys 371:179–190. doi:10.1006/abbi.1999.1454
Zurawska U, Baribeau DA, Giilck S, Victor C, Gandhi S, Florescu A, Verma S (2013) Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients. Curr Oncol 20:e539–e545. doi:10.3747/co.20.1523
Funding
XZ was supported by the China Scholarship Council (CSC) with a 2-year stipend (File No 201508080093). SDS salary was supported by the University Paul Sabatier in Toulouse (France).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Zhang, X., Harbeck, N., Jeschke, U. et al. Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer. J Cancer Res Clin Oncol 143, 1107–1122 (2017). https://doi.org/10.1007/s00432-016-2325-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-016-2325-y